Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Melina K. Grasmeier"'
Autor:
Melina K. Grasmeier, Anna F. Langmann, Peter Langmann, Matthias Treiber, Markus A. Thaler, Peter B. Luppa
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Background: Antibodies to infliximab (ATI) in serum are associated with secondary loss of response (LOR) to infliximab (IFX) therapy in patients with inflammatory bowel disease (IBD). However, feasible ATI-related predictors of therapy success are la
Externí odkaz:
https://doaj.org/article/2a752b3c17864cdf8a98722fd95e6822
Publikováno v:
Clinical Chemistry and Laboratory Medicine (CCLM). 61:1255-1265
Objectives The therapeutic antibody infliximab (IFX) has improved the life quality of numerous autoinflammatory disease patients. However, IFX can trigger the generation of anti-drug antibodies (ADA), whose optimal evaluation and management are curre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1e3c982e4928119e1c0fa159da9fe5d
https://doi.org/10.1515/cclm-2022-0949
https://doi.org/10.1515/cclm-2022-0949
Autor:
Peter B. Luppa, Matthias Treiber, Melina K. Grasmeier, Markus Thaler, P Langmann, Anna F. Langmann
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Therapeutic Advances in Gastroenterology
Therapeutic Advances in Gastroenterology
Background: Antibodies to infliximab (ATI) in serum are associated with secondary loss of response (LOR) to infliximab (IFX) therapy in patients with inflammatory bowel disease (IBD). However, feasible ATI-related predictors of therapy success are la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03fa08e0422b04af6a04a851fd21608c
https://doi.org/10.1177/17562848211037849
https://doi.org/10.1177/17562848211037849